There's no reason that Covidien (COV) "shouldn't" be
one of the top-performers in large med-tech, nor enjoy some of the best
multiples. If there's a more consistent performer (to the good side),
I can't immediately think of it, and management has built this company
to deliver strong performance on a lasting basis. Not buying these
shares a year or two ago goes down as a sizable regret in my personal
investing history, but I would caution investors to resist the
temptation to chase this name.
Please continue here:
Covidien Delivers Yet Again, But Valuation Is Plenty Fair
No comments:
Post a Comment